entertainment -WSS

entertainment

author：knowledge 2025-08-28 13:07:29 - browse：4764

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： The explosion of genetic testing requires a new approach

focus

knowledge

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

Researchers explore possible ties between long Covid, menopause

First Opinion Podcast: Long Covid needs a new approach

Beam Therapeutics to lay off 20% of its staff, re

What to expect at HLTH 2023, the health care industry conference

Hospital price transparency does save money, advocate argues

leisure time

entertainment

knowledge

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: GSK CEO on pharma giant's new direction

Duchenne breakthrough therapy leaves behind pioneering families

VC firm General Catalyst wants to buy a health system

Alkermes shareholders re

Lawmakers consider Medicare pay reforms for doctors

Supreme Court strikes down use of affirmative action

NIH confirmation hearing shows politicization of research

Jerome Adams on the need for new antivirals for Covid

Bill would stop addiction treatment from triggering child abuse inquiry

explore

FDA struggles to regulate food additives, sometimes for decades

UnitedHealth’s board chair also owns a personal investment firm

HHS leader on health, climate change and biopharma emissions

Senate committee scrutinizes Medicare Advantage brokers

Physician executives need more than on

2023 STAT Wunderkinds: get to know the winners

focus

focus

knowledge

focus